Abstract:IMPORTANCE Concurrent chemoradiotherapy has been the standard treatment for stage II nasopharyngeal carcinoma (NPC) based on data using 2-dimensional conventional radiotherapy. There is limited evidence for the role of chemotherapy with use of intensity-modulated radiation therapy (IMRT). OBJECTIVE To assess whether concurrent chemotherapy can be safely omitted for patients with low-risk stage II/T3N0 NPC treated with IMRT. DESIGN, SETTING, AND PARTICIPANTS This multicenter, open-label, randomized, phase 3, noninferiority clinical trial was conducted at 5 Chinese hospitals, including 341 adult patients with low-risk NPC, defined as stage II/T3N0M0 without adverse features (all nodes <3 cm, no level IV/Vb nodes; no extranodal extension; Epstein-Barr virus DNA <4000 copies/mL), with enrollment between November 2015 and August 2020. The final date of follow-up was March 15, 2022. INTERVENTIONS Patients were randomly assigned to receive IMRT alone (n = 172) or concurrent chemoradiotherapy (IMRT with cisplatin, 100 mg/m(2) every 3 weeks for 3 cycles [n = 169]). MAIN OUTCOMES AND MEASURES The primary end point was 3-year failure-free survival (time from randomization to any disease relapse or death), with a noninferiority margin of 10%. Secondary end points comprised overall survival, locoregional relapse-free survival, distant metastasis-free survival, adverse events, and health-related quality of life (QOL) measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30; range, 0-100 points; minimum clinically important difference >= 10 for physical function, symptom control, or health-related QOL; higher score indicates better functioning and global health status or worse symptoms). RESULTS Among 341 randomized patients (mean [SD] age, 48 [10] years; 30% women), 334 (98.0%) completed the trial. Median follow-up was 46 months (IQR, 34-58). Three-year failure-free survival was 90.5% for the IMRT-alone group vs 91.9% for the concurrent chemoradiotherapy group (difference, -1.4%; 1-sided 95% CI, -7.4% to infinity; P value for noninferiority, <.001). No significant differences were observed between groups in overall survival, locoregional relapse, or distant metastasis. The IMRT-alone group experienced a significantly lower incidence of grade 3 to 4 adverse events (17% vs 46%; difference, -29% [95% CI, -39% to -20%]), including hematologic toxicities (leukopenia, neutropenia) and nonhematologic toxicities (nausea, vomiting, anorexia, weight loss, mucositis). The IMRT-alone group had significantly better QOL scores during radiotherapy including the domains of global health status, social functioning, fatigue, nausea and vomiting, pain, insomnia, appetite loss, and constipation. CONCLUSIONS AND RELEVANCE Among patients with low-risk NPC, treatment with IMRT alone resulted in 3-year failure-free survival that was not inferior to concurrent chemoradiotherapy.

Effect of Hypoxic Radiosensitizer Sodium Glycididazole on Long-Term Result of Radiotherapy for Nasopharyngeal Carcinoma

Effectiveness and safety of sodium glycididazole for nasopharyngeal carcinoma radiotherapy:a Meta-analysis

Short-term Effectiveness of Glycididazolum Natrium Combined with Radiotherapy for Patients with Advanced Non-Small-cell Lung Cancer

Clinical Study on Short-Term Curative Effects and Early Side Reactions of CMNa on the Radiotherapy of Nasopharyngeal Carcinoma

A Phase III Multicenter Trial of Radiosensitizing Effect and Safety of Sodium Glycididazole in Thoracic Esophegeal Squamous Carcinoma

Therapeutic effect of sodium glycididazole combined with radiotherapy on the aged lo-coregionally advanced cervical cancer

Preliminary Study of Conventional Radiotherapy Combined with Nicotinamide and Carbogen in the Treatment for Nasopharyngeal Carcinoma

Radiosensitization of Sodium Glycididazole for Patients with Esophageal Squamous Cell Carcinoma: Interim Results of Randomized Multicenter Trial

Therapeutic effect and prognostic analysis of 164 cases of nasopharyngeal carcinoma after radiotherapy

A Randomized Phase 2 Trial of Induction Chemotherapy and Concurrent Chrono-chemotherapy with Radiation Therapy in Locally Advanced Nasopharyngeal Carcinoma

A double blind radomized stage Ⅱ clinical trial of radiosensitizer Metronidazole-amino-acidum-natrium(CMNa) with concurrent chemoradiotherapy for thorax segment esophageal carcinoma

Meta Analysis of 3D-CRT Radiosensitivity on Non-Small Cell Lung Cancer by Metronidazole Amino Acidum Natrium

Reducing Target Volumes of Intensity-Modulated Radiotherapy Following Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Analysis of Follow-Up Results of Chronotherapy and Conventional Chemotherapy Combined with IMRT for Locally Advanced Nasopharyngeal Carcinoma

Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma A Randomized Clinical Trial

Correlation of Hypoxia Status with Radiosensitizing Effects of Sodium Glycididazole: A Preclinical Study

The research of clinical effect of paclitaxel liposome plus oxaliplatin combined with radiotherapy for advanced nasopharyngeal carcinoma

Progress Report of A Randomized Trial Comparing Long-Term Survival and Late Toxicity of Concurrent Chemoradiotherapy with Adjuvant Chemotherapy Versus Radiotherapy Alone in Patients with Stage Iii to Ivb Nasopharyngeal Carcinoma from Endemic Regions of China

Comparison of efficacy and adverse reactions between radiotherapy combined with cisplatin and radiotherapy combined with nimotuzumab in treatment of locally advanced nasopharyngeal carcinoma

Radiotherapy Combined with Chemotherapy in the Treatment of Patients with Advanced Nasopharyngeal Carcinoma